Dinlas Pharma EPZ Ltd Faces Scrutiny Over Alleged Employee Mistreatment and Controversial Manufacturing/Expiry Date Irregularities



An exposé has revealed mistreatment of employees at Dinlas Pharma EPZ Ltd, shedding light on controversial discrepancies in manufacturing and expiry dates. 

After enduring years of hardship, employees of Dinlas Pharma EPZ Ltd have bravely come forward to shed light on the challenging work environment they have been subjected to. 

The company has faced serious allegations from both current and former employees, including reports of unsafe working conditions, inadequate compensation, and intimidation tactics. 

According to accounts from current and former employees, workers at the facility have been regularly handling hazardous materials without the necessary protective gear, exposing them to the risk of workplace accidents, chemical burns, and long-term health issues. 

These safety concerns are further compounded by claims of stagnant wages that have failed to keep up with the rising cost of living in Kenya. Employees have also voiced grievances about being required to work additional shifts, cover for absent colleagues, and report to work on public holidays without receiving overtime pay or extra allowances. 

In addition to the lack of compensation for extra duties, workers have reported facing retaliation when attempting to raise concerns about their pay, safety standards, or working conditions. Allegations suggest that employees who question these issues often face intimidation or unjust dismissal, particularly at the time of contract renewal. 

These claims paint a troubling picture of a profitable enterprise that allegedly prioritizes financial gain over the well-being of its employees, a concern echoed by labor advocates familiar with challenges in Kenya’s industrial sector. 

Calls have now been made for labor rights groups and relevant authorities to investigate whether Dinlas Pharma EPZ Ltd is adhering to the Employment Act, the Occupational Safety and Health Act (OSHA), and minimum wage regulations. 

As the allegations continue to gain attention, employees emphasize their fundamental demands: fair compensation, safe working conditions, and the freedom to speak out without fear of reprisal.

Another Kenyan has also demanded answers.

 I would like to seek clarification from healthcare professionals, pharmacists, procurement experts, and members of the public regarding a concern I recently observed with medicines issued at a government health facility.

I was issued children's syrup from a government facility with the following details:

Date of manufacture: October 2023

Expiry date: September 2026

Date issued to patient: May 2026

The medicine in question is PARADOL (Paracetamol Oral Solution BP), manufactured by Dinlas Pharma EPZ Ltd in Mombasa, Kenya. The packaging appears professionally printed and bears the manufacturer's details and a registration number.

My concern is whether it is normal for children's syrups to remain in government stores and health facilities for such a long period before being dispensed to patients. By the time the medicine was issued, it only had a few months remaining before expiry.

As a parent with a young family, I have noticed that some syrups issued from government facilities appear to be approaching their expiry dates. This has raised questions in my mind about stock management, inventory turnover, and how medicines are distributed within public health facilities.

I am not making any allegations and I do not have sufficient information to draw any conclusions. However, I would appreciate hearing from pharmacists, medical practitioners, supply chain experts, and other parents who may have had similar experiences, particularly in Nairobi and other government health facilities across the country.

Is it standard practice for medicines manufactured in 2023 to still be in circulation and being dispensed in 2026 if they remain within their approved shelf life? How does the government pharmaceutical supply chain manage stock rotation for commonly used pediatric medicines?

I am also interested in knowing whether other parents have received medicines with similar manufacturing and expiry timelines from government facilities and whether this is considered normal within the healthcare system.

I am simply seeking information and public views to better understand how these medicines move through the public healthcare supply chain and whether there is anything that members of the public should know when receiving medicines that are nearing their expiry dates.

Thank you.

Comments

Popular posts from this blog

Inside Mwenda Thuranira’s growing lead over incumbent MP in Isiolo North

South C Tragedy Prompts Pleas for Immediate Action by Sakaja Against City Hall Officers

Public Statement on the South C Building Collapse — Nairobi